{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T20:40:48Z","timestamp":1792269648786,"version":"4.4.0"},"reference-count":12,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T00:00:00Z","timestamp":1788739200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Anti-p200 pemphigoid is a rare autoimmune subepidermal blistering disease with limited evidence guiding its management. We report a 49-year-old woman with refractory anti-p200 pemphigoid who failed treatment with high-dose prednisone and dapsone and developed significant corticosteroid-related toxicity, including hypertension, hypertrichosis, steroid-induced myopathy, and psychological distress. Given her history of complicated diverticulitis requiring bowel resection, dupilumab was initiated as a steroid-sparing therapeutic option. Pruritus improved within two weeks, near-complete remission was achieved after two months, and sustained disease control was maintained for six months, allowing substantial corticosteroid tapering without treatment-related adverse events.<\/jats:p>","DOI":"10.3389\/fimmu.2026.1922276","type":"journal-article","created":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T05:34:42Z","timestamp":1788759282000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Case Report: Dupilumab as a steroid-sparing therapeutic option in refractory anti-p200 pemphigoid: real-world effectiveness in a patient with significant comorbidities"],"prefix":"10.3389","volume":"17","author":[{"given":"Aikaterini","family":"Kyriakou","sequence":"first","affiliation":[{"name":"B Dermatology Clinic, Aristotle University School of Medicine, Papageorgiou General Hospital","place":["Thessaloniki, Greece"]},{"name":"Center of Expertise on AIBD, B Dermatology Department, Aristotle University School of Medicine, Papageorgiou General Hospital","place":["Thessaloniki, Greece"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christos","family":"Minas","sequence":"additional","affiliation":[{"name":"Aristotle University of Thessaloniki","place":["Thessaloniki, Greece"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonios","family":"Fantakis","sequence":"additional","affiliation":[{"name":"1 Surgical Department, Aristotle University School of Medicine, Papageorgiou General Hospital","place":["Thessaloniki, Greece"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Athanasia","family":"Tsaousi","sequence":"additional","affiliation":[{"name":"B Dermatology Clinic, Aristotle University School of Medicine, Papageorgiou General Hospital","place":["Thessaloniki, Greece"]},{"name":"Center of Expertise on AIBD, B Dermatology Department, Aristotle University School of Medicine, Papageorgiou General Hospital","place":["Thessaloniki, Greece"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anastasia","family":"Tsitlakidou","sequence":"additional","affiliation":[{"name":"B Dermatology Clinic, Aristotle University School of Medicine, Papageorgiou General Hospital","place":["Thessaloniki, Greece"]},{"name":"Center of Expertise on AIBD, B Dermatology Department, Aristotle University School of Medicine, Papageorgiou General Hospital","place":["Thessaloniki, Greece"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Parthena","family":"Meltzanidou","sequence":"additional","affiliation":[{"name":"B Dermatology Clinic, Aristotle University School of Medicine, Papageorgiou General Hospital","place":["Thessaloniki, Greece"]},{"name":"Center of Expertise on AIBD, B Dermatology Department, Aristotle University School of Medicine, Papageorgiou General Hospital","place":["Thessaloniki, Greece"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthi-Maria","family":"Lazaridi","sequence":"additional","affiliation":[{"name":"B Dermatology Clinic, Aristotle University School of Medicine, Papageorgiou General Hospital","place":["Thessaloniki, Greece"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandra","family":"Fleva","sequence":"additional","affiliation":[{"name":"Center of Expertise on AIBD, Department of Immunology - Histocompatibility, Papageorgiou General Hospital","place":["Thessaloniki, Greece"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anastasia","family":"Giannakou","sequence":"additional","affiliation":[{"name":"Center of Expertise on AIBD, Department of Immunology - Histocompatibility, Papageorgiou General Hospital","place":["Thessaloniki, Greece"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisavet","family":"Lazaridou","sequence":"additional","affiliation":[{"name":"B Dermatology Clinic, Aristotle University School of Medicine, Papageorgiou General Hospital","place":["Thessaloniki, Greece"]},{"name":"Center of Expertise on AIBD, B Dermatology Department, Aristotle University School of Medicine, Papageorgiou General Hospital","place":["Thessaloniki, Greece"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aikaterini","family":"Patsatsi","sequence":"additional","affiliation":[{"name":"B Dermatology Clinic, Aristotle University School of Medicine, Papageorgiou General Hospital","place":["Thessaloniki, Greece"]},{"name":"Center of Expertise on AIBD, B Dermatology Department, Aristotle University School of Medicine, Papageorgiou General Hospital","place":["Thessaloniki, Greece"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,9,7]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"1\u20137","DOI":"10.1111\/jdv.70370","article-title":"Incidence of p200 pemphigoid: A nationwide study","author":"Jouen","year":"2026","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.839094","article-title":"Coexistence of anti-p200 pemphigoid and psoriasis: A systematic review","volume":"13","author":"Xie","year":"2022","journal-title":"Front Immunol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.15961","article-title":"Treatment and clinical outcomes in anti-p200 pemphigoid: A systematic review","volume":"34","author":"Laufer Britva","year":"2020","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.2007.07810.x","article-title":"Anti-p200 pemphigoid in a 17-year-old girl successfully treated with systemic corticosteroid and dapsone","volume":"156","author":"Yamane","year":"2007","journal-title":"Br J Dermatol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1016\/j.jdcr.2017.01.028","article-title":"Successful treatment of severe anti-p200 pemphigoid in a heart transplant recipient with a single cycle of rituximab","volume":"3","author":"Rousseau","year":"2017","journal-title":"JAAD Case Rep"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.12163","article-title":"A successful treatment with ustekinumab in a case of antilaminin-gamma1 pemphigoid associated with psoriasis","volume":"168","author":"Majima","year":"2013","journal-title":"Br J Dermatol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1684\/ejd.2018.3280","article-title":"A case of anti-laminin gamma1 (p200) pemphigoid with psoriasis vulgaris successfully treated with apremilast","volume":"28","author":"Waki","year":"2018","journal-title":"Eur J Dermatol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1111\/ddg.15364","article-title":"Successful treatment with guselkumab of anti-p200 pemphigoid associated with plaque psoriasis","volume":"22","author":"Kitayama","year":"2024","journal-title":"J Dtsch Dermatol Ges"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1111\/1346-8138.16864","article-title":"Anti-laminin gamma1 (p200) pemphigoid successfully treated with tofacitinib combined with prednisone","volume":"50","author":"Zhou","year":"2023","journal-title":"J Dermatol"},{"key":"B10","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1016\/j.jdcr.2025.02.051","article-title":"Anti-p200 pemphigoid with autoantibodies targeting laminin beta-4 and clinical response to methotrexate","volume":"64","author":"Siebmanns","year":"2025","journal-title":"JAAD Case Rep"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2026.1767277","article-title":"A case report of IgA-mediated anti-laminin-gamma1 (p200) pemphigoid successfully treated with stapokibart combined with corticosteroids","volume":"17","author":"Zhang","year":"2026","journal-title":"Front Immunol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1016\/j.annder.2020.08.053","article-title":"Refractory bullous pemphigoid with IgE anti-BP230 and IgG anti-p200 antibodies successfully treated with omalizumab","volume":"148","author":"Sarrazin","year":"2021","journal-title":"Ann Dermatol Venereol"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1922276\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T05:34:43Z","timestamp":1788759283000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1922276\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,7]]},"references-count":12,"alternative-id":["10.3389\/fimmu.2026.1922276"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1922276","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,7]]},"article-number":"1922276"}}